• Board of Directors

    • Thomas Staab, BioCryst Pharmaceuticals, Board Chairman
    • Tom Adams, Pairwise Plants
    • Gray Armstrong, Pfizer
    • Chuck Blatchley, Grifols
    • Christopher Capel, Smith Anderson
    • Joe Cascone, Mayne Pharma
    • David Chapin, Forma Life Science Marketing
    • Matthew Cooke, Davis Moore Capital
    • Terry Costello, Royal Hill Consulting
    • Jay Dixon, PPD
    • Bill Edwards, Merz North America
    • Mike Elder, Novozymes
    • Tom Fagley, Hughes Pittman & Gupton
    • Ed Field, BioLabs North Carolina
    • Neal Fowler, Liquidia Technologies
    • Maeve Gardner, GlaxoSmithKline
    • Mike Garrett, TCG
    • Mark Harbaugh, Bioventus
    • Erica Jackson, K&L Gates
    • Christof Jensen, UCB
    • Matt Keffer, PricewaterhouseCoopers
    • Scott Kohne, BASF 
    • William Lee, Cato Bioventures
    • Susan Lillard Thomason, IQVIA
    • Ted Lithgow, Humacyte
    • Mike McBrierty, Biogen
    • Martin Meeson, Fujifilm Diosynth Biotechnologies
    • Sheila Mikhail, Asklepios BioPharmaceutical
    • Kyle Rasbach, Pappas Capital
    • Russ Read, National Center for Biotechnology Workforce
    • Scott Sewell, Cook Medical
    • Oliver Sherrill, Alexandria Real Estate Equities
    • Giles Shih, BioResource International
    • Gary Shope, Patheon
    • Andy Stober, Novartis Pharmaceuticals
    • Brad Walters, RTI International
    • Rich West, Baebies
    • Tim Willis, MED1 Ventures 
    • Adam Zerda, BD (Becton, Dickinson & Co.)